semaglutide tablets south africa Africa's Market Opens To Generic Competition Novo Nordisk wins EU approval

RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)

GLP-1 medications work partly by suppressing appetite

Results: No associations were found between the number of CMBs and the measures for microglial activation ( = 2.6*e-5, p = 0.050) and BBB leakage ( = -0.0001, p = 0.400) in the white matter

Glutathione reduces the very signal (oxidative stress) that tells the melanocytes to start producing melanin